Know Cancer

or
forgot password

The Association Between Alpha 1 Acid Glycoprotein Level and Outcome of Patients With Metastatic Cancer Treated With Docetaxel Based Chemotherapy


N/A
18 Years
N/A
Not Enrolling
Both
Metastatic Lung Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Metastatic Prostate Cancer, Metastatic Bladder Cancer

Thank you

Trial Information

The Association Between Alpha 1 Acid Glycoprotein Level and Outcome of Patients With Metastatic Cancer Treated With Docetaxel Based Chemotherapy


Docetaxel based chemotherapy is a standard therapy in various metastatic cancers including
non small cell lung cancer, breast cancer, gastric cancer, prostate cancer, and bladder
cancer.

One of the main plasma protein carriers of docetaxel is Alpha 1 acid glycoprotein

Retrospective data suggests that plasma level of alpha 1 acid glycoprotein is associated
with the outcome of docetaxel based therapy in non small cell lung cancer patients.

The investigators aim to prospectively study the association between the baseline plasma
level of alpha 1 acid glycoprotein (measured on the first day of the first cycle of
docetaxel) and the outcome (response rete, progression free survival, overall survival) of
docetaxel based therapy in patients with metastatic non small cell lung cancer, breast
cancer, stomach cancer, prostate cancer, and bladder cancer.

Inclusion Criteria


Inclusion Criteria

- patients with metastatic cancer from lung, breast, gastric, prostate, and bladder
origin

- patients must be treated with docetaxel based chemotherapy

- patients must sign an informed consent form

Exclusion Criteria

- patients with metastatic cancer other than lung, breast, gastric, prostate, and
bladder origin

- patients treated with chemotherapy other than docetaxel

- patients that did not sign an informed consent form

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

The association between the baseline plasma level of alpha 1 acid glycoprotein and progression free survival of docetaxel based therapy in patients with metastatic cancer

Outcome Description:

The association between the baseline plasma level of alpha 1 acid glycoprotein and progression free survival of docetaxel based therapy in patients with metastatic non small cell lung cancer, breast cancer, gastric cancer, prostate cancer, and bladder cancer

Outcome Time Frame:

3 years

Safety Issue:

No

Principal Investigator

Daniel Keizman, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Meir Medical Center

Authority:

Israel: Ministry of Health

Study ID:

A1AGP1234

NCT ID:

NCT01814150

Start Date:

April 2013

Completion Date:

April 2018

Related Keywords:

  • Metastatic Lung Cancer
  • Metastatic Breast Cancer
  • Metastatic Gastric Cancer
  • Metastatic Prostate Cancer
  • Metastatic Bladder Cancer
  • Docetaxel
  • Alpha 1 Acid Glycoprotein
  • Outcome
  • Urinary Bladder Neoplasms
  • Breast Neoplasms
  • Lung Neoplasms
  • Stomach Neoplasms
  • Neoplasm Metastasis
  • Prostatic Neoplasms

Name

Location